Combination therapy for the management of hypertension: A review of the evidence

American Journal of Health-System Pharmacy

Volumn 67, Issue 11, 2010, Pages 885-894

  Sood, Nitesh ^a   Reinhart, Kurt M ^b   Baker, William L ^c  

^a HARTFORD HOSPITAL   (United States)

^b WINGATE UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Angiotensin antagonists; Angiotensin converting enzyme inhibitors; Calcium antagonists; Cardiovascular diseases; Combined therapy; Diuretics; Dosage; Hypertension; Hypotensive agents; Protocols; Toxicity

Indexed keywords

ALISKIREN PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; AMLODIPINE PLUS VALSARTAN; ANTIHYPERTENSIVE AGENT; ATENOLOL PLUS CHLORTALIDONE; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BENDROFLUMETHIAZIDE PLUS NADOLOL; BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL PLUS HYDROCHLOROTHIAZIDE; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPROSARTAN PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS METOPROLOL; HYDROCHLOROTHIAZIDE PLUS MOEXIPRIL; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS PROPRANOLOL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS TIMOLOL MALEATE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LISINOPRIL; TIMOLIDE; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIDIURESIS; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIURETIC THERAPY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MONOTHERAPY; PATHOGENESIS; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; VASOCONSTRICTION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; PRACTICE GUIDELINE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 77955866484     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp090419     Document Type: Review

References (62)

1. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 117:e25-146.
2. Chobanian AV, Bakris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42:1206-52. (Pubitemid 37553153)
3. Lawes CM, Vander Hoorn S, Rogers A, for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008; 371:1513-8.
4. Mancia G, DeBacker G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2007; 25:1105-87. [Erratum, J Hypertens. 2007; 25:1749.]
5. Ong KL, Cheung BM, Man YB et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007; 49:69-75.
6. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363:2022-31. (Pubitemid 38781102)
7. Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004; 363:2049-51. (Pubitemid 38781107)
8. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61.
9. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J Clin Hypertens. 2004; 4:393-404. (Pubitemid 35469393)
10. Black HR, Elliott WJ, Grandits G et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003; 289:2073-82. (Pubitemid 37430209)
11. Brunner HR, Menard J, Waeber B et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens. 1990; 8:3-11. (Pubitemid 20186307)
12. Struijker-Boudier HA, Ambrosioni E, Helzgreve et al. The need for combination antihypertensive therapy to reach target blood pressures: what has been learned from clinical practice and morbiditymortality trials. Int J Clin Pract. 2007; 61:1592-602. (Pubitemid 47228597)
13. Law MR, Wald NJ, Morris JK et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ. 2003; 326:1427-34.
14. Wald DS, Law M, Morris JK et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122:290-300.
15. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007; 120:713-9. (Pubitemid 47176510)
16. Gehr TW, Sica DA, Frishman WH. Diuretic therapy in cardiovascular disease. In: Frishman WH, Sonnenblick EH, Sica DA, eds. Cardiovascular pharmacotherapeutics, 2nd ed. New York: McGraw-Hill; 2003:157-76.
17. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004; 43:4-9. (Pubitemid 38031903)
18. Psaty BM, Furberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. JAMA. 2004; 292:43-4. (Pubitemid 38923792)
19. Veterans Administration Cooperative Study Group on Hypertensive Agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol. 1983; 52:1230-7.
20. Pareek A, Karnik N, Salagre SB et al. Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage 1 hypertensive patients: a multicenter, randomized, controlled study. Curr Med Res Opin. 2008; 24:1771-9. (Pubitemid 351929074)
21. Chrysant SG. Antihypertensive effectiveness of low-dose lisinoprilhydrochlorothiazide combination. Arch Intern Med. 1994; 154:737-43. (Pubitemid 24115660)
22. Neutel JM, Franklin SS, Oparil S et al. Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens. 2006; 8:850-7.
23. Villamil A, Chrysant SG, Calhoun D et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007; 25:217-26. (Pubitemid 44885684)
24. Weir MR, Ferdinand KC, Flack JM et al. A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. Hypertension. 2005; 46:508-13. (Pubitemid 41376830)
25. Dahlof B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366:895-906. (Pubitemid 41265663)
26. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359:995-1003. (Pubitemid 34286536)
27. Zillich AJ, Garg J, Basu S et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006; 48:219-24. (Pubitemid 44309815)
28. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE Study). J Hypertens. 2003; 21:1563-74. (Pubitemid 36994137)
29. Gillespie EL, White CM, Kardas M et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on development of new-onset type 2 diabetes. Diabetes Care. 2005; 28:2261-6. (Pubitemid 41242483)
30. Weir MR. Calcium channel blockers: their pharmacologic and therapeutic role in hypertension. Am J Cardiovasc Drugs. 2007; 7(suppl 1):5-15.
31. Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazeprilamlodipine on cardiac nitric oxide, cGMP, and TNF-∞ production after cardiac ischemia. J Cardiovasc Pharmacol. 2006; 47:636-42. (Pubitemid 44309655)
32. Ruschitzka FT, Luscher TF. Is there a rationale for combining angiotensin-converting enzyme inhibitors and calcium antagonists in cardiovascular disease? Am Heart J. 1997; 134:s31-47.
33. Jamerson KA, Nwose O, Jean-Louis L et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens. 2004; 17:495-501. (Pubitemid 38726163)
34. Sharma A, Bagchi A, Kinagi SB et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther. 2007; 29:2667-76.
35. Flack JM, Calhoun DA, Satlin L et al. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009; 23:479-89.
36. Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290:2805-16. (Pubitemid 37509488)
37. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359:2417-28.
38. Davis BR, Whelton PK; for the ALLHAT Collaborative Research Group. Benazepril plus amlodipine or hydrochlorothiazide for hypertension. N Engl J Med. 2009; 360:1148-9. Letter.
39. Ernst ME, Barter BL, Basile JN. All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective. J Clin Hypertens. 2009; 11:5-10. Editorial.
40. Pedrinelli R, Dell'Omo G, Mariani M. Calcium channel blockers, postural vasoconstriction and dependent edema in essential hypertension. J Hum Hypertens. 2001; 15:455-61. (Pubitemid 32640260)
41. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens. 2003; 5:330-5.
42. Schrader J, Salvetti A, Calvo C et al. The combination of amlodipine/valsartan 5/160 mg produces less peripheral edema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. Int J Clin Pract. 2009; 63:217-25.
43. De la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the reninangiotensin system. J Hum Hypertens. 2009; 23:503-11.
44. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension. 2005; 46:880-6. (Pubitemid 40628932)
45. Oparil S, Yarows SA, Patel S et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007; 370:221-9. [Erratum, Lancet. 2007; 370:1542.]
46. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349:1893-906. (Pubitemid 37409706)
47. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547-59.
48. Khan NA, Hemmelgarn B, Herman RJ et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol. 2009; 25:287-98.
49. National Institute for Health and Clinical Excellence. Hypertension: management of hypertension in adults in primary care. www.nice.org.uk/CG034 (accessed 2009 Oct 16).
50. Lindholm LH, Carlberg B, Samuelsson O. Should β-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366:1545-53. (Pubitemid 41540112)
51. Bradley HA, Wiysonge CS, Volmink JA et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and metaanalysis. J Hypertens. 2006; 24:2131-41. (Pubitemid 44611017)
52. Khan N, McAlister FA. Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006; 174:1737-42. (Pubitemid 43893565)
53. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008; 52:1482-9.
54. White WB. Improving blood pressure control and clinical outcomes through initial use of combination therapy in stage 2 hypertension. Blood Press Monit. 2008; 13:123-9. (Pubitemid 351416914)
55. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002; 62:443-62. (Pubitemid 34208333)
56. Payne KA, Esmonde-White S. Observational studies of antihypertensive medication use and compliance: is drug choice a factor in treatment adherence? Curr Hypertens Rep. 2000; 2:515-24.
57. Denzi CM. Medication noncompliance: what is the problem? Manag Care. 2000; 9(suppl):7-12.
58. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart. 1998; 80:437-41. (Pubitemid 28535528)
59. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug costs: a systematic review. PloS Med. 2007; 4:e283.
60. Phillips LS, Branch WT, Cook CB. Clinical inertia. Ann Intern Med. 2001; 135:825-34. (Pubitemid 33051266)
61. Okonofua EC, Simpson KN, Jesri A et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension. 2006; 47:345-51. (Pubitemid 43740273)
62. Berlowitz DR, Ash AS, Hickey EC et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339:1957-63. (Pubitemid 29024127)